Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Atrys Health, S.A. is a Spain-based biomedical company specializing in precision diagnostic services and oncology treatments. Founded in 2007 and headquartered in Madrid, it operates through segments including Diagnosis, Oncology, and Preventive Medicine, delivering integrated solutions like structural and molecular pathology, genetics, nuclear medicine, telemedicine in radiology, cardiology, ophthalmology, dermatology, and advanced therapies such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy. With over 2,200 professionals across eight countries, including Spain, Portugal, and Latin America, Atrys Health emphasizes a 360-degree approach from prevention to cancer treatment, leveraging technology for telediagnosis and personalized care. The company, formerly Althia Health, pioneered telemedicine and radiotherapy innovations, integrating 14 acquisitions since 2018 for robust growth in laboratory testing, tele-diagnostics, and corporate health plans. Classified in the healthcare sector's biotechnology industry, it supports hospitals, insurers, and businesses with research-driven services.
€2.59
+€0.01 (+0.39%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-4.07% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 8.5%, steady but not accelerating. Margins contracted 8.6pp, which offsets some of the top-line progress.
Negative free cash flow of -€14M. The business is consuming cash, not generating it. Operating margin contracted 8.6pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€141M
▲ +8.5% YoY
Net Income (TTM)
-€101M
▼ -214.2% YoY
Op. Margin
-4.07%
▼ -8.6pp YoY
ROIC
-0.99%
▼ -1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€14M
▼ -38.8% YoY
Op. Cash Flow (TTM)
-€8M
▼ -23.6% YoY
Net Debt
€245M
Cash & Equiv.
€13M
3Y CAGR: -3.8%
Continue Research